test

James Silverman

@Opaleye Management Inc.

Latest period2024 - Q3ReportedManaged Assets$599.558MTotal holdings44
Assets growth rate37%Assets growth rate (2-Q avg)16.19%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Opaleye Management Inc.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 44 positions.

Assets under management

The assets under management (AUM) of Opaleye Management Inc. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 599.558M in assets, with a quarterly growth rate of 37% and a 2-quarter average growth rate of 16.19%. The portfolio is managed by James Silverman, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
ARVNArvinas Inc
Recent Activity
Increased 126.13%
5.16%
$30.911M
1.255M shares@ $24.63 avg price
CDXSCodexis Inc
Recent Activity
Increased 153.84%
4.51%
$27.012M
8.77M shares@ $3.08 avg price
KROSKeros Therapeutics Inc
Recent Activity
Increased 7.56%
3.83%
$22.954M
395,276 shares@ $58.07 avg price
IMNMImmunome Inc
Recent Activity
Increased 12.25%
3.02%
$18.092M
1.238M shares@ $14.62 avg price
LQDALiquidia Corporation
Recent Activity
Increased 422.51%
2.84%
$16.981M
1.698M shares@ $10.0 avg price
ETONEton Pharmaceuticals Inc
Recent Activity
Increased 16.08%
2.79%
$16.68M
2.78M shares@ $6.0 avg price
NRIXNurix Therapeutics Inc
Recent Activity
Increased 0.26%
1.58%
$9.437M
420,000 shares@ $22.47 avg price
SLRNAcelyrin Inc
Recent Activity
Increased 19.86%
1.56%
$9.336M
1.894M shares@ $4.94 avg price
NUVLNuvalent Inc
Recent Activity
Increased 7.93%
1.1%
$6.547M
64,000 shares@ $102.3 avg price
NAMSNewamsterdam Pharma Company
Recent Activity
Increased 6.35%
0.93%
$5.561M
335,000 shares@ $16.6 avg price